Results 41 to 50 of about 721 (146)

Varespladib: targeting the inflammatory face of atherosclerosis [PDF]

European Heart Journal, 2010
This editorial refers to ‘Randomized trial of an inhibitor of secretory phospholipase A2 on atherogenic lipoprotein subclasses in statin-treated patients with coronary heart disease’, by R.S. Rosenson et al., doi:10.1093/eurheartj/ehq374 Atherosclerosis is a complex disease and in its pathogenesis depends on the interaction between lipoproteins and ...
Arsenault, Benoit J., Boekholdt, S. Matthijs, Kastelein, John J. P.   +2 more
openaire   +3 more sources

Role of Phospholipases A2 in Vascular Relaxation and Sympatholytic Effects of Five Australian Brown Snake, Pseudonaja spp., Venoms in Rat Isolated Tissues

Frontiers in Pharmacology, 2021
Human envenoming by Australian brown snakes (Pseudonaja spp.) may result in potentially life-threatening hypotension and subsequent cardiovascular collapse.
Nhi Thuc Vuong, Timothy N. W. Jackson, Christine E. Wright   +2 more
doaj   +1 more source

Modulation of immunity by the secreted phospholipase A2 family

Immunological Reviews, Volume 317, Issue 1, Page 42-70, August 2023., 2023
Summary Among the phospholipase A2 (PLA2) superfamily, which typically catalyzes the sn‐2 hydrolysis of phospholipids to yield fatty acids and lysophospholipids, the secreted PLA2 (sPLA2) family contains 11 isoforms in mammals. Individual sPLA2s have unique enzymatic specificity toward fatty acids and polar heads of phospholipid substrates and display ...
Makoto Murakami, Hiroyasu Sato, Yoshitaka Taketomi   +2 more
wiley   +1 more source

Pathogenic roles of neutrophil‐derived alarmins (S100A8/A9) in heart failure: From molecular mechanisms to therapeutic insights

British Journal of Pharmacology, Volume 180, Issue 5, Page 573-588, March 2023., 2023
An excessive neutrophil count is recognized as a valuable predictor of inflammation and is associated with a higher risk of adverse cardiac events in patients with heart failure. Our understanding of the effectors used by neutrophils to inflict proinflammatory actions needs to be advanced.
Bo Bai, Yun Xu, Haibo Chen
wiley   +1 more source

Plasma proteins, cognitive decline, and 20‐year risk of dementia in the Whitehall II and Atherosclerosis Risk in Communities studies

Alzheimer's &Dementia, Volume 18, Issue 4, Page 612-624, April 2022., 2022
Abstract Introduction Plasma proteins affect biological processes and are common drug targets but their role in the development of Alzheimer's disease and related dementias remains unclear. We examined associations between 4953 plasma proteins and cognitive decline and risk of dementia in two cohort studies with 20‐year follow‐ups.
Joni V. Lindbohm, Nina Mars, Keenan A. Walker, Archana Singh‐Manoux, Gill Livingston, Eric J. Brunner, Pyry N. Sipilä, Kalle Saksela, Jane E. Ferrie, Ruth C. Lovering, Stephen A. Williams, Aroon D. Hingorani, Rebecca F. Gottesman, Henrik Zetterberg, Mika Kivimäki   +14 more
wiley   +1 more source

Engineering Antivenom: Research Progress and Future Directions in Snakebite Envenoming Therapy. [PDF]

Ann N Y Acad Sci
Snakebite envenoming therapy is evolving from plasma‐derived antivenoms toward rationally engineered therapeutics. Advances in toxicovenomics, structural biology, antibody engineering, computational protein design, recombinant expression, small‐molecule inhibitors, and diagnostics are enabling toxin‐centric development of safer, more effective, and ...
Laustsen AH.
europepmc   +2 more sources

Action of Varespladib (LY-315920), a Phospholipase A2 Inhibitor, on the Enzymatic, Coagulant and Haemorrhagic Activities of Lachesis muta rhombeata (South-American Bushmaster) Venom

Frontiers in Pharmacology, 2022
Varespladib (VPL) was primarily developed to treat inflammatory disturbances associated with high levels of serum phospholipase A2 (PLA2). VPL has also demonstrated to be a potential antivenom support agent to prevent PLA2-dependent effects produced by ...
Pamella G. Gutierres, Diego R. Pereira, Nataly L. Vieira, Lilian F. Arantes, Nelson J. Silva, Kristian A. Torres-Bonilla, Stephen Hyslop, Karen Morais-Zani, Rosa M. B. Nogueira, Edward G. Rowan, Rafael S. Floriano   +10 more
doaj   +1 more source

Prodrug Strategies in Atherosclerosis: Targeted Delivery and Therapeutic Advances. [PDF]

Cardiovasc Ther
Atherosclerosis is an advancing and complex vascular condition primarily associated with sustained inflammatory responses, oxidative imbalance, and disruptions in lipid homeostasis. These pathological features render it a major contributor to the global burden of cardiovascular disease, encompassing both morbidity and mortality.
Mirhadi E, Almahmeed W, Kesharwani P, Sahebkar A.   +3 more
europepmc   +2 more sources

Novel Drug Design for Treatment of COVID‐19: A Systematic Review of Preclinical Studies

Canadian Journal of Infectious Diseases and Medical Microbiology, Volume 2022, Issue 1, 2022., 2022
Background. Since the beginning of the novel coronavirus (SARS‐CoV‐2) disease outbreak, there has been an increasing interest in discovering potential therapeutic agents for this disease. In this regard, we conducted a systematic review through an overview of drug development (in silico, in vitro, and in vivo) for treating COVID‐19. Methods.
Sarah Mousavi, Shima Zare, Mahmoud Mirzaei, Awat Feizi, Siddhartha Pati   +4 more
wiley   +1 more source

Comparative Effectiveness of Anti‐Inflammatory Drug Treatments in Coronary Heart Disease Patients: A Systematic Review and Network Meta‐Analysis

Mediators of Inflammation, Volume 2021, Issue 1, 2021., 2021
Introduction and Hypothesis. The role of inflammation is widely recognized in the pathogenesis of coronary artery disease. Research on animal models had shown the potential benefits of targeting specific inflammatory pathways. However, studies on human subjects are limited with small number of patients and no head‐to‐head comparisons. Methods.
Ivan Wudexi, Elica Shokri, Mohamed Abo-Aly, Kazuhiro Shindo, Ahmed Abdel-Latif, Helen C. Steel   +5 more
wiley   +1 more source